% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Kordelas:277771,
      author       = {L. Kordelas and T. Terzer$^*$ and T. A. Gooley and C. Davis
                      and B. M. Sandmaier and M. L. Sorror and O. Penack and N. D.
                      E. Schaeper and I. W. Blau and D. W. Beelen and A.
                      Radujkovic and P. Dreger and T. Luft},
      title        = {{EASIX}-1 year and late mortality after allogeneic stem
                      cell transplantation.},
      journal      = {Blood advances},
      volume       = {7},
      number       = {18},
      issn         = {2473-9529},
      address      = {Washington, DC},
      publisher    = {American Society of Hematology},
      reportid     = {DKFZ-2023-01486},
      pages        = {5374-5381},
      year         = {2023},
      note         = {#EA:C060# / 2023 Sep 26;7(18):5374-5381},
      abstract     = {Patients with haematological malignancies who survive the
                      first year after allogeneic stem cell transplantation
                      (alloSCT) without relapse have a substantial risk of
                      non-relapse mortality (NRM), and predictive markers are
                      missing. The Endothelial Activation and Stress Index (EASIX)
                      predicts endothelial complications and NRM early after
                      alloSCT. We hypothesised that EASIX assessed 1 year after
                      alloSCT in disease-free survivors may predict late NRM.
                      Relapse-free survivors at one year after alloSCT were
                      retrospectively studied in two independent cohorts (training
                      cohort: n=610, merged validation cohort: n=852). EASIX
                      determined one year after alloSCT was correlated with
                      overall survival (OS), NRM, and relapse. Serum endothelial
                      and inflammatory markers were measured in the training
                      cohort and correlated with EASIX-1y. EASIX-1year predicted
                      OS and NRM but not relapse risk in both, training and
                      validation cohort in univariable and multivariable Cox
                      regression analyses. Brier score and c-index analyses
                      validated the univariable EASIX effects. There was no
                      significant interaction between EASIX-1year and incidence of
                      chronic GvHD on OS. EASIX-1year predicted outcome
                      irrespective of pre-existing comorbidities. Principal causes
                      of NRM in both, training and validation cohorts were
                      infections with and without GvHD, as well as cardiovascular
                      complications. EASIX-1y correlated with sCD141 and
                      interleukin-18, but not with C-reactive protein, suppressor
                      of tumorigenicity (ST)-2, angiopoietin-2, CXCL9 or CXCL8.
                      EASIX-1year is the first validated predictor of late overall
                      and non-relapse mortality. High-risk patients as defined by
                      EASIX-1year might be considered for intensified surveillance
                      and prophylactic measures.},
      cin          = {C060},
      ddc          = {610},
      cid          = {I:(DE-He78)C060-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37477588},
      doi          = {10.1182/bloodadvances.2022008617},
      url          = {https://inrepo02.dkfz.de/record/277771},
}